Compare Stocks: SNDX, LGND, CGON, and KOD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$67.38 -1.4%	$74.10	$35.80 ▼ $80.97	$5.97B	0.28	980,794 shs	1.54 million shs
KOD Kodiak Sciences	$94.45 -4.1%	$43.53	$10.94 ▼ $104.00	$5.94B	2.03	3.37 million shs	2.67 million shs
LGND Ligand Pharmaceuticals	$302.96 +0.1%	$291.44	$175.89 ▼ $326.63	$6.04B	1.14	259,162 shs	179,227 shs
SNDX Syndax Pharmaceuticals	$17.60 -3.4%	$19.27	$12.99 ▼ $25.59	$1.56B	0.42	1.73 million shs	2.56 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+0.34%	-9.35%	-4.24%	+70.76%
KOD Kodiak Sciences	0.00%	+191.96%	+159.76%	+145.07%	+499.30%
LGND Ligand Pharmaceuticals	0.00%	+0.48%	+4.56%	-5.19%	+69.19%
SNDX Syndax Pharmaceuticals	0.00%	-3.30%	-14.89%	-19.34%	+12.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$67.38 -1.4%	$74.10	$35.80 ▼ $80.97	$5.97B	0.28	980,794 shs	1.54 million shs
KOD Kodiak Sciences	$94.45 -4.1%	$43.53	$10.94 ▼ $104.00	$5.94B	2.03	3.37 million shs	2.67 million shs
LGND Ligand Pharmaceuticals	$302.96 +0.1%	$291.44	$175.89 ▼ $326.63	$6.04B	1.14	259,162 shs	179,227 shs
SNDX Syndax Pharmaceuticals	$17.60 -3.4%	$19.27	$12.99 ▼ $25.59	$1.56B	0.42	1.73 million shs	2.56 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+0.34%	-9.35%	-4.24%	+70.76%
KOD Kodiak Sciences	0.00%	+191.96%	+159.76%	+145.07%	+499.30%
LGND Ligand Pharmaceuticals	0.00%	+0.48%	+4.56%	-5.19%	+69.19%
SNDX Syndax Pharmaceuticals	0.00%	-3.30%	-14.89%	-19.34%	+12.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	30.27% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$100.43	6.33% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$337.89	11.53% Upside
SNDX Syndax Pharmaceuticals	2.82	Moderate Buy	$41.80	137.50% Upside

Current Analyst Ratings Breakdown

Latest SNDX, LGND, CGON, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
10/1/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/1/2026	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/30/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$103.00
9/29/2026	SNDX Syndax Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
9/28/2026	KOD Kodiak Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$112.00
9/28/2026	KOD Kodiak Sciences	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$85.00 ➝ $145.00
9/28/2026	KOD Kodiak Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$80.00 ➝ $120.00
9/28/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$58.00 ➝ $96.00
9/25/2026	LGND Ligand Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$345.00
9/24/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$36.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,478.36	N/A	N/A	$9.33 per share	7.22
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
LGND Ligand Pharmaceuticals	$268.09M	22.53	$7.85 per share	38.58	$51.68 per share	5.86
SNDX Syndax Pharmaceuticals	$172.35M	9.05	N/A	N/A	$0.74 per share	23.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	32.40	36.28	2.45	67.88%	20.06%	11.68%	11/5/2026 (Estimated)
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)

Latest SNDX, LGND, CGON, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
KOD Kodiak Sciences	N/A	2.49	2.49
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
KOD Kodiak Sciences	89.06%
LGND Ligand Pharmaceuticals	91.28%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
KOD Kodiak Sciences	44.40%
LGND Ligand Pharmaceuticals	5.60%
SNDX Syndax Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
SNDX Syndax Pharmaceuticals	298	88.61 million	84.36 million	Optionable

SNDX, LGND, CGON, and KOD Headlines

Recent News About These Companies

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 2 at 4:01 PM | globenewswire.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Crosses Below 50 Day Moving Average - Time to Sell?

October 2 at 3:41 AM | americanbankingnews.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Cross Below Fifty Day Moving Average - Here's What Happened

October 2 at 3:39 AM | marketbeat.com

Contrasting Syndax Pharmaceuticals (NASDAQ:SNDX) and Fate Therapeutics (NASDAQ:FATE)

October 1 at 5:44 AM | americanbankingnews.com

Jefferies Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

September 29, 2026 | streetinsider.com

Diaceutics accelerates growth on precision medicine demand

September 29, 2026 | ca.finance.yahoo.com

Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases

September 28, 2026 | seekingalpha.com

Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts

September 25, 2026 | seekingalpha.com

Diaceutics PLC And Syndax Pharmaceuticals, Inc. Expand Multi-Year Relay Partnership

September 24, 2026 | marketscreener.comM

Bank of America Corp DE Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX

September 19, 2026 | marketbeat.com

Syndax Pharmaceuticals stock gains on investor conference schedule and steady September trading

September 18, 2026 | ad-hoc-news.deA

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 14, 2026 | marketbeat.com

WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX

September 13, 2026 | marketbeat.com

Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX

September 11, 2026 | marketbeat.com

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6% - Here's Why

September 10, 2026 | marketbeat.com

Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX

September 7, 2026 | marketbeat.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Syndax Announces Participation in September Investor Conferences

September 1, 2026 | globenewswire.com

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

August 24, 2026 | invezz.comI

Syndax (SNDX) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SNDX, LGND, CGON, and KOD Company Descriptions

CG Oncology NASDAQ:CGON

$67.38 -0.97 (-1.42%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$67.44 +0.06 (+0.09%)

As of 10/2/2026 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Kodiak Sciences NASDAQ:KOD

$94.45 -4.01 (-4.07%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$94.29 -0.16 (-0.17%)

As of 10/2/2026 07:59 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Ligand Pharmaceuticals NASDAQ:LGND

$302.96 +0.22 (+0.07%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$303.06 +0.10 (+0.03%)

As of 10/2/2026 07:30 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Syndax Pharmaceuticals NASDAQ:SNDX

$17.60 -0.62 (-3.40%)

As of 10/2/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNDX, LGND, CGON, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNDX, LGND, CGON, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNDX, LGND, CGON, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SNDX, LGND, CGON, and KOD Company Descriptions

CG Oncology NASDAQ:CGON

Kodiak Sciences NASDAQ:KOD

Ligand Pharmaceuticals NASDAQ:LGND

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNDX, LGND, CGON, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNDX, LGND, CGON, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNDX, LGND, CGON, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SNDX, LGND, CGON, and KOD Company Descriptions

CG Oncology NASDAQ:CGON

Kodiak Sciences NASDAQ:KOD

Ligand Pharmaceuticals NASDAQ:LGND

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools